araag2/HINT huggingface dataset:
Clinical trial NCT01106079 (phase 3, status: completed)
Conditions: psoriatic arthritis
ICD codes: L40.52
Drugs: intensive management or tight control, standard management - control group
SMILES: CC1=CC(O)=CC(C)=C1Cl, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with a diagnosis of psoriatic arthritis by a consultant Rheumatologist with
             less than 24 months disease duration.

          -  Active disease defined by at least one tender or swollen joint or active enthesitis.

          -  Age ≥18 years at the time of signing the informed consent form and either male or
             female patients.

          -  Patient understands the objectives of the study and is able and willing to sign the
             Informed Consent Form.

          -  Men and women of child bearing potential (WCBP) must use at least one adequate birth
             control measure for the duration of the study and should continue such precautions for
             6 months after receiving the last dose of protocol treatment.

          -  Adequate full blood count within 28 days before randomisation:

               -  Haemoglobin count > 8.5 g/dL

               -  White blood count (WBC) > 3.5 x 10*9/L

               -  Absolute neutrophil count (ANC) > 1.5 x 10*9/L

               -  Platelet count > 100 x 10*9/L

          -  Adequate hepatobiliary function within 28 days before randomisation:

             *ALT and/or AST levels must be within 3 times the upper limit of normal range (ULN)
             for the laboratory conducting the test.

          -  The patient must be able to adhere to the study visit schedule and other protocol
             requirements.

        Exclusion Criteria:

          -  Previous treatment for articular disease with disease modifying drugs (DMARDs)
             including, but not limited to, methotrexate, sulfasalazine, leflunomide,

          -  Women who are pregnant, lactating or planning pregnancy within 6 months of their last
             dose of protocol treatment.

          -  Use of any investigational agents within 4 weeks or within 5 half-lives of the
             investigational agent, whichever is longer, prior to randomisation.
Clinical trial NCT00201981 (phase 3, status: completed)
Conditions: keratoconjunctivitis sicca
ICD codes: H16.223, H16.221, H16.222, H16.229
Drugs: rebamipide
SMILES: OC(=O)C(CC1=CC(O)=NC2=CC=CC=C12)NC(=O)C1=CC=C(Cl)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  must have symptoms of dry eye for a minimum of 6 months

          -  must be able to sign and date an informed consent

        Exclusion Criteria:

          -  presence of anterior segment disease

          -  glaucoma or ocular hypertension

          -  using Restasis

          -  use of topically instilled ocular medications during study

          -  use of contact lenses

          -  history of ocular surgery within 12 months

          -  females who are pregnant, breast feeding, or child-bearing potential and not willing
             to remain abstinent or use contraception

          -  presence of Stevens-Johnson syndrome

          -  any anticipated change in medication through-out study

          -  concurrent involvement in another study or previous receipt of this drug

          -  cannot be safely be weaned off of ocular medications
Clinical trial NCT00252694 (phase 3, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: candesartan
SMILES: CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female aged 37 - 75 years with type 2 diabetes diagnosed at age of 36 years or
             thereafter.

          -  Duration of diabetes for > 1 year and < 20 years with stable diabetic therapy within
             last 6 months.

          -  Patients with untreated resting mean sitting SBP < 130 mmHg and mean sitting DBP < 85
             or treated resting mean SBP < 160 mmHg and mean sitting DBP < 90 mmHg with retinal
             photograph grading level >20/10 up to < 47/47 (on ETDRS severity scale).

        Exclusion Criteria:

          -  Patients with the following conditions are excluded from participation in the study:

          -  Cataract or media opacity of a degree which precludes taking gradable retinal
             photographs

          -  Angle closure glaucoma, which precludes pharmacological dilatation of the pupil

          -  History of or presence of proliferative retinopathy

          -  History or presence of clinical significant macular oedema (CSME)

          -  History or evidence of photocoagulation of the retina

          -  Other retinal conditions which may mask assessment, eg, retinal vein occlusion

          -  Positive micral dipstick test

          -  Presence of secondary diabetes

          -  Pregnant or lactating women or women of child bearing potential not practicing an
             adequate method of contraception

          -  Need of treatment with ACE-inhibitor

          -  Haemodynamically significant aortic or mitral valve stenosis

          -  Known renal artery stenosis or kidney transplantation

          -  Hypersensitivity to study drug

          -  Severe concomitant disease which may interfere with the assessment of the patient, eg,
             malignancy, as judged by the investigator
Clinical trial NCT00241345 (phase 3, status: terminated)
Conditions: cytomegalovirus infections
ICD codes: P35.1
Drugs: valganciclovir, ganciclovir
SMILES: CC(C)[C@H](N)C(=O)OCC(CO)OCN1C=NC2=C1NC(N)=NC2=O, NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1
Reason stopped: 
    due to low accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients receiving allogeneic peripheral blood stem cell transplant from either a
             related or unrelated donor at Washington University Medical Center.

          -  An initial episode of CMV viremia.

          -  At the time of randomization:

               -  ANC greater than or equal to 1000

               -  Age greater than or equal to 18

               -  Adequate renal function with creatinine clearance greater than 10 ml/min

               -  Total bilirubin less than or equal to 3.0

        Exclusion Criteria:

          -  Current GI graft versus host disease grade III-IV

          -  Development of CMV disease prior to or at the time of the first detection of CMV
             viremia by PCR

          -  Uncontrolled emesis or diarrhea (greater than or equal to 4 episodes per day) for 2
             consecutive days

          -  Pregnant or nursing female patient

          -  Known hypersensitivity to ganciclovir
Clinical trial NCT00608023 (phase 3, status: completed)
Conditions: lipodystrophy, hiv infections
ICD codes: E88.1, Z21
Drugs: tesamorelin, placebo for tesamorelin
SMILES: CC\C=C\CC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(N)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects who have completed the 26 weeks treatment period of the TH9507-CTR-1011
             study.

          -  Signed informed consent before any trial-related activities.

        Exclusion Criteria:

          -  Fasting blood glucose >8.33 mmoL (150 mg/dL) at the end of the TH9507-CTR-1011 study.
Clinical trial NCT00000577 (phase 3, status: withdrawn)
Conditions: asthma, lung diseases
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40, J84.115, M05.10, M05.111, M05.112, M05.119, M05.121, M05.122
Drugs: albuterol, colchicine, adrenal cortex hormones, adrenergic-beta agonists
SMILES: CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O
Reason stopped: 
    record is an acrn grant summary & not reflective of an individual trial. all acts conducted by
    acrn were individually registered on the prs.
  
Eligibility criteria:

        Patients with asthma; specific eligibility criteria vary for each study.
Clinical trial NCT00326105 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: quetiapine fumarate
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Patient is able to provide written informed consent before beginning any study related
             procedures

          -  Patient has a documented clinical diagnosis of major depressive disorder

          -  Patient is able to understand and comply with the requirements of the study, as judged
             by a study investigator

        Exclusion Criteria:

          -  Patients with a history of non-compliance as judged by the study investigator

          -  Patients with a known lack of response to previous treatment with quetiapine

          -  Patients who have participated in a clinical trial within 4 weeks of randomization
Clinical trial NCT01200758 (phase 3, status: completed)
Conditions: non-hodgkin's lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: rituximab sc, rituximab iv, cyclophosphamide, doxorubicin, vincristine, prednisone/prednisolone
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Cluster of differentiation 20 (CD20)-positive, follicular Non-Hodgkin's lymphoma grade
             1, 2, 3a. A tumor biopsy must have been performed within 6 months before study entry
             with material available for central review

          -  No prior treatment

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

        Exclusion Criteria:

          -  Grade 3b follicular lymphoma

          -  Transformation to high-grade lymphoma secondary to follicular lymphoma

          -  Types of Non-Hodgkin's lymphoma other than follicular lymphoma

          -  Presence or history of central nervous system (CNS) disease

          -  Corticoid therapy during the last 4 weeks, except prednisone treatment less than (<)
             20 milligrams per day (mg per day)

          -  Known active bacterial, viral, fungal, or mycobacterial, or any major episode of
             infections requiring hospitalization or treatment with IV antibiotics within 4 weeks
             of start of study medication, or oral antibiotics within 2 weeks prior to start of
             study medication
Clinical trial NCT00680186 (phase 3, status: completed)
Conditions: thromboembolism
ICD codes: O88.22, O88.23, O88.211, O88.212, O88.213, O88.219
Drugs: warfarin, dabigatran etexilate
SMILES: S1SSSSSSS1, CCCCCCOC(=O)\N=C(\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1
Eligibility criteria:

        Inclusion criteria:

          -  Acute symptomatic uni- or bilateral Deep Vein Thrombosis (DVT) of the leg involving
             proximal veins, and/or Pulmonary Embolism (PE)

          -  Male or female, being 18 years of age or older

          -  Written informed consent for study participation

        Exclusion criteria:

          -  Persistent symptoms of VTE

          -  PE requiring urgent intervention

          -  Use of vena cava filter

          -  Contraindications to anticoagulant therapy

          -  Allergy to study medications

          -  Elevated Aspartate-aminotransferase (AST) or Alanine-aminotransferase (ALT) > 3x Upper
             Limit of Normal (ULN) or known liver disease expected to have an impact on survival

          -  Severe renal impairment

          -  Patients considered unsuitable for inclusion
Clinical trial NCT00425100 (phase 3, status: completed)
Conditions: overactive bladder
ICD codes: N32.81
Drugs: fesoterodine fumarate
SMILES: CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(OC(=O)C(C)C)C=CC(CO)=C1)C(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  OAB patients who present with OAB symptoms(≥8 micturitions and ≥3 urgency episodes per
             24 h documented in the baseline bladder diary)

          -  OAB patients dissatisfied with their prior therapy with tolterodine

        Exclusion Criteria:

          -  Patients with any contraindication to fesoterodine usage, e.g., urinary retention,
             gastric retention, uncontrolled narrow-angle glaucoma, or known hypersensitivity to
             the drug or its ingredients.

          -  Patients with significant hepatic and renal disease or other significant unstable
             diseases.

          -  OAB symptoms caused by neurological conditions, known pathologies of urinary tract,
             etc.
Clinical trial NCT00509262 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2, renal insufficiency, chronic
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44, N25.0, Q61.4, N23, N26.9, P96.0, Q60.0, Q60.1
Drugs: sitagliptin, glipizide, placebo for sitagliptin, placebo for glipizide
SMILES: N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, CC1=NC=C(N=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Has type 2 diabetes mellitus

          -  Has moderate or severe renal insufficiency

        Exclusion Criteria:

          -  Has type 1 diabetes mellitus or a history of ketoacidosis

          -  Is on a new weight loss program

          -  Has active liver disease

          -  Is on dialysis or is likely to need dialysis during the study
Clinical trial NCT00387881 (phase 3, status: completed)
Conditions: migraine, without aura
ICD codes: G43.019, G43.009, G43.719, G43.011, G43.119, G43.709, G43.001
Drugs: sumatriptan succinate / naproxen sodium, placebo
SMILES: CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  At least a 6 month history of probably migraine (6 migraine attacks per month)

          -  Males and women of childbearing potential on a adequate contraception.

        Exclusion Criteria:

          -  Physician diagnosis of migraine; history of triptan or ergot use; history of headache
             prophylaxis use

          -  Pregnant and/or nursing mother

          -  History of cardiovascular disease.

          -  Uncontrolled hypertension.

          -  Basilar or Hemiplegic migraine

          -  History of stroke or transient ischemic attacks (TIA).

          -  History of epilepsy or treated with anti-epileptics within the past 5 years.

          -  Impaired hepatic or renal function.

          -  History of gastrointestinal bleeding or ulceration.

          -  Allergy or hypersensitivity to Aspirin or any other NSAID.

          -  Allergy or hypersensitivity to triptans.

          -  Participated in an investigational drug trial in the previous 4 weeks.
Clinical trial NCT00428792 (phase 3, status: completed)
Conditions: attention deficit hyperactivity disorder
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: methylphenidate 20 mg long-acting capsules
SMILES: COC(=O)C(C1CCCCN1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Children aged 6-12

          -  Diagnosis of Attention-Deficit Hyperactivity Disorder (ADHD)

          -  Current medication with either 20 mg or 40 mg immediate release methylphenidate

        Exclusion Criteria:

          -  Concomitant psychiatric disorders requiring pharmacological treatment

          -  Concomitant severe somatic disorders

          -  Eating disorders

          -  Addiction disorders

          -  Very high or low body weight according to age

          -  Known hypersensitivity to methylphenidate

          -  Contraindications for methylphenidate

        Other protocol-defined inclusion/exclusion criteria applied to the study.
Clinical trial NCT00175890 (phase 3, status: completed)
Conditions: epilepsy, partial
ICD codes: G40.111, G40.119, G40.211, G40.219, G40.101, G40.109, G40.201
Drugs: levetiracetam
SMILES: CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Pediatric patients from 1 month to less than 4 years of age

          -  Pediatric patients diagnosed with refractory partial onset seizures, on a stable
             regimen of one to two other anti-epileptic drugs and at least 2 partial onset seizures
             per week in the two weeks prior to screening

          -  Patients must have two partial onset seizures (with corresponding clinical event)
             during the 48-hour video EEG at screening

        Exclusion Criteria:

          -  A ketogenic diet

          -  Previous exposure to levetiracetam

          -  Seizures too close together to count accurately

          -  Treatable seizure etiology

          -  Current diagnosis of Lennox-Gastaut Syndrome or epilepsy secondary to a progressing
             cerebral disease

          -  Diagnosis of a terminal illness
Clinical trial NCT01054092 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: ipragliflozin
SMILES: OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(F)C(CC2=CC3=CC=CC=C3S2)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetic patients for at least 12 weeks

          -  HbA1c value between 6.5 and 9.5%

          -  Body Mass Index ( BMI )20.0 - 45.0kg/m2

        Exclusion Criteria:

          -  Type 1 diabetes mellitus patients

          -  Serum creatinine > upper limit of normal

          -  Proteinuria (albumin/creatinine ratio > 300mg/g)

          -  Dysuria and/or urinary tract infection, genital infection

          -  Significant renal, hepatic or cardiovascular diseases

          -  Severe gastrointestinal diseases

          -  Proliferative diabetic retinopathy
Clinical trial NCT00628589 (phase 3, status: completed)
Conditions: patients with schizophrenia and acute agitation
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: inhaled loxapine 5 mg, inhaled loxapine 10 mg, inhaled placebo
SMILES: CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2, CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female adult patients with schizophrenia and acute agitation

        Exclusion Criteria:

          -  Agitation caused primarily by acute intoxication

          -  History of drug or alcohol dependence

          -  Treatment with benzodiazepines or other hypnotics within 4 hours prior to study drug
             administration
Clinical trial NCT01258673 (phase 3, status: completed)
Conditions: essential hypertension
ICD codes: I10, O10.02, O10.03, O10.011, O10.012, O10.013, O10.019
Drugs: fimasartan/hctz combination, fimasartan
SMILES: CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female outpatients 18 years of age and older

          -  Patients with antihypertensive agents at screening: DBP<110mmHg or Patients without
             antihypertensive agents at screening: DBP 90mmHg~120mmHg

          -  Subjects who agree to participate in this sudy and give written informed consent

          -  Subjects considered to understand the study, be cooperative, and able to be
             followed-up until the end of the study

          -  Patients with not controlled blood pressure at baseline visit, by fimasartan 60mg
             4weeks treatment, DBP 90mmHg~109mmHg and SBP<180mmHg

        Exclusion Criteria:

          -  The sitting DBP is more than 120mmHg or severe hypertensive patient with sitting
             systolic blood pressure over 200mmHg Patients with secondary hypertension

          -  Patients who are measured the mean difference of mean blood pressure under SiDBP
             10mmHg or SiSBP 20mmHg at screening or baseline visit

          -  Patients with severe renal(Creatinine more 1.5 times than upper limit of normal),
             gastrointestinal, hematological or hepatic(AST, ALT more 2 twice more than upper limit
             of normal)disease etc. which might affect absorption, disposition, metabolism or
             excretion of the drug

          -  Patients with postural hypotension

          -  Patients with sever insulin dependent diabetes mellitus or uncontrolled diabetes
             mellitus(HbA1c>9%, regimen change of oral hypoglycemic agents within 12weeks, treated
             insulin before screening)

          -  Patients with a history of myocardial infarction, severe coronary artery disease or
             clinically significant heart failure or valvular defect in last 6 months

          -  Patients with consumptive disease, autoimmune disease, connective tissue disease

          -  Patients with a history of type B or C hepatitis(include carrier)

          -  Patients with HIV or hepatitis

          -  Patients with clinically significant laboratory abnormality

          -  Patients receiving any drugs known to affect blood pressure or medical treatments that
             can influence the blood pressure

          -  Patients with allergy or contraindication to any angiotensin II receptor antagonists

          -  Female of childbearing potential who does not undergo hysterectomy or is not
             post-menopausal

          -  Patients judged to have a history of alcohol or drug abuse by the investigator

          -  Patients participated other clinical trial 12 weeks before Screening - Patients judged
             to be inappropriate for this study by the investigator with other reasons
Clinical trial NCT00547521 (phase 3, status: completed)
Conditions: rheumatoid arthritis (ra)
ICD codes: M05.9, M06.08, M06.00, M06.011, M06.012, M06.019, M06.021
Drugs: abatacept, methotrexate (mtx)
SMILES: [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of Rheumatoid Arthritis

          -  Subjects Global Disease Assessment of greater than equal to 20 mm on a visual analog
             scale

          -  Discontinue all Biologics and Disease-modifying antirheumatic drugs (DMARDS) except
             for methotrexate

        Exclusion Criteria:

          -  Received treatment with rituximab

          -  Subjects who have received treatment with immunoadsorbtion columns (such as Prosorba
             columns), mycophenolate mofetil (Cellcept®), cyclosporine A or other calcineurin
             inhibitors, or D-Penicillamine